AtaiBeckley (ATAI) Operating Leases (2022 - 2026)

AtaiBeckley's (ATAI) quarterly Operating Leases came in at $1.7 million in Q1 2026, down 6.16% quarter-over-quarter from $1.8 million in Q4 2025.

AtaiBeckley (ATAI) Operating Leases (2022 - 2026) Analysis & Trends

AtaiBeckley's Operating Leases history runs 3 years deep, the most recent figure standing at $1.7 million for Q1 2026.

On a quarterly basis, Operating Leases changed N/A year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.8 million, up 146.04% from the prior year.
Operating Leases slipped to $1.7 million in Q1 2026 per ATAI's latest filing, from $1.8 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $2.6 million in Q2 2025 to a low of $44000.0 in Q4 2022.
A 4-year average of $1.3 million and a median of $1.0 million in 2023 frame the typical range for Operating Leases.
Biggest YoY gain for Operating Leases was 146.04% in 2025; the steepest drop was 146.04% in 2025.
Year by year, Operating Leases stood at $732000.0 in 2024, then soared by 146.04% to $1.8 million in 2025, then decreased by 6.16% to $1.7 million in 2026.
Per Business Quant, the three latest ATAI Operating Leases figures stand at $1.7 million (Q1 2026), $1.8 million (Q4 2025), and $732000.0 (Q4 2024).

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AtaiBeckley	2.56 Bn	2.56 Bn	-

Download Data